NeuroMetrix, a medical device company, and Omron Medical Devices, a subsidiary of Omron Healthcare China, have entered into an agreement for the distribution of NC-stat DPNCheck in China.

Pursuant to the terms of the agreement, NeuroMetrix will be the exclusive distributor for Omron Medical Devices’ NC-stat DPNCheck in China.

NC-stat DPNCheck is a rapid, accurate and quantitative point-of-care test for early detection of diabetic peripheral neuropathy.

Diabetic peripheral neuropathy causes significant morbidity including pain, increased risk of falling in the elderly, and is the primary trigger for diabetic foot ulcers that may require lower extremity amputations.

Japan-based healthcare consulting firm Orient Strategy facilitated this partnership between NeuroMetrix and Omron Healthcare China.

Omron Healthcare China chairman Hiroto Iwasa noted recent studies of diabetes in China highlight the dramatic need for innovative and proven technology such as the NC-stat DPNCheck to address the neuropathic complications of this disease.

"Our ongoing work in Japan preparing for the imminent NC-stat DPNCheck launch there has reinforced our positive assessment of the technology and its suitability for the China market," Iwasa added.

NeuroMetrix and Omron Healthcare have announced a partnership in earlier 2013 for the exclusive distribution of NC-stat DPNCheck in Japan.